Reimbursed Care Access in United States Minor Outlying Islands

Currently classified as a strictly controlled substance under federal scheduling (Schedule I) with no authorized medical use outside of approved clinical research. Possession, distribution, and manufacture are prohibited under the Controlled Substances Act; limited exceptions at the federal level exist only for DEA- and IRB-approved clinical trials or narrow, case-by-case religious exemptions that have been litigated separately. #.

Currently classified as a strictly controlled substance under federal scheduling (Schedule I) with no authorized medical use outside of approved clinical research. MDMA can be accessed legally only within DEA/IND-authorized clinical trials (for example, late‑stage MAPS-sponsored PTSD trials), but it is not an FDA-approved, reimbursable medicine. Research access requires IND/IDE/DEA registration and institutional oversight. #.

Esketamine (marketed as SPRAVATO) is an FDA‑approved medication for certain depressive indications and is legally available under federal law when administered within certified treatment settings. The FDA originally approved esketamine nasal spray (SPRAVATO) in 2019 and has since expanded indications in supplemental approvals; SPRAVATO is a Schedule III controlled substance and is subject to a Risk Evaluation and Mitigation Strategy (REMS) that requires administration and monitoring in certified healthcare settings and prohibits patient self‑administration at home. # #.

Regulatory body and coverage: The regulatory oversight is federal (FDA for approval/labeling; DEA for scheduling; CMS and private insurers for reimbursement/coverage decisions). Because SPRAVATO must be administered in certified clinics (REMS), reimbursement is handled on a payer‑by‑payer basis: private commercial insurers may cover SPRAVATO under medical benefit policies subject to medical-necessity criteria (often for treatment‑resistant depression or MDD with acute suicidality consistent with the FDA label), and Medicare/Medicaid coverage follows national and local Medicare Administrative Contractor (MAC) and state Medicaid rules — coverage is not automatic and typically requires documentation of prior treatment failures and that administration occurs in an approved setting. (See FDA labeling and REMS requirements for administration/monitoring details.) #.

State/territory nuance for U.S. Minor Outlying Islands: These islands do not operate an independent drug‑approval or reimbursement system and fall under U.S. federal law; any clinical administration would have to comply with FDA/DEA/REMS rules and with whatever federal healthcare delivery or contractor arrangements exist for that territory (in practice, most residents or personnel receive care through U.S. mainland systems).

Ketamine (racemic ketamine) is a Schedule III controlled substance under federal law and is an accepted medical anesthetic and analgesic; it is widely used off‑label in psychiatry for depressive disorders in specially arranged clinical settings. The DEA classifies ketamine as Schedule III (federal controls apply). #.

Clinical and reimbursement context: Ketamine is not FDA‑approved specifically for depression (except as racemic ketamine formulations used as anesthetics), but many healthcare providers administer intravenous, intramuscular, or off‑label intranasal ketamine for treatment‑resistant depression under medical supervision. These off‑label uses are governed by standard medical practice and state medical board rules; reimbursement for off‑label ketamine psychiatric infusions varies widely. Commercial insurers and Medicare generally do not provide routine coverage for off‑label ketamine infusions for depression (coverage decisions are payer‑specific and often denied as investigational), so most patients pay out‑of‑pocket or obtain limited coverage when billed under allowable medical codes (e.g., infusion/administration CPT codes) for medically documented indications. The FDA has issued safety communications about compounded ketamine nasal sprays and emphasizes that compounded nasal products are not FDA‑approved. # #.

Regional/territory nuance: In U.S. Minor Outlying Islands, federal scheduling and medical practice standards apply; local healthcare delivery is extremely limited, so practical access would generally require evacuation/transfer to U.S. mainland providers or specially arranged federal medical services.

Currently classified as a strictly controlled substance under federal scheduling (Schedule I) with no authorized medical use outside of approved clinical research. Non‑research possession, distribution, or manufacture is prohibited. Narrow religious exemptions for sacramental use (e.g., in the UDV litigation) have been recognized in specific court orders but are exceptional and fact‑specific. # #.

Currently classified as a strictly controlled substance under federal scheduling (Schedule I) with no authorized medical use outside of approved clinical research. Possession, distribution, and manufacture are prohibited except under DEA‑authorized research. (Some 5‑MeO positional isomers and analogues are explicitly controlled; enforcement can also rely on the Federal Analogue Act for substances substantially similar to Schedule I agents.) #.

Currently classified as a strictly controlled substance under federal scheduling (Schedule I) with no authorized medical use outside of approved clinical research. Ibogaine is not FDA‑approved; clinical use within the U.S. is effectively prohibited outside of carefully authorized research or special regulatory permissions. Recent interest and state‑level research funding initiatives do not change its federal Schedule I status. # #.

Because ayahuasca preparations contain DMT (a Schedule I substance), they are generally illegal under federal law except in narrowly tailored, court‑recognized religious exemptions (for example, the Supreme Court’s decision in Gonzales v. O Centro recognized a RFRA‑based right for a particular religious organization to import and use hoasca/ayahuasca under a judicially‑supervised exemption). Outside those very specific religious exemptions, ayahuasca is treated as a Schedule I controlled substance and has no authorized medical use except in DEA/FDA‑authorized clinical research. # #.

Mescaline is classified as a Schedule I controlled substance under federal law; however, a statutory religious exemption applies to the non‑drug ceremonial use of peyote by members of the Native American Church, and courts have further developed narrow religious‑use doctrine. Outside those narrow, legally recognized religious exemptions, mescaline possession or distribution is unlawful except in DEA/FDA‑authorized research. # #.

Compounds in the 2C series (e.g., 2C‑B, 2C‑I and related analogues) are treated as Schedule I controlled substances under federal law or are prosecutable under the Federal Analogue Act where explicit scheduling is absent. They have no authorized medical use except in DEA/FDA‑authorized research. Enforcement and specific scheduling can vary by individual 2C compound, but the practical legal status for non‑research use remains prohibition. #.